Insider Transactions in Q1 2021 at Cytokinetics Inc (CYTK)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 22
2021
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-0.69%
|
$125,000
$25.19 P/Share
|
|
Mar 22
2021
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+0.69%
|
$30,000
$6.15 P/Share
|
|
Mar 19
2021
|
L Patrick Gage Director |
SELL
Open market or private sale
|
Direct |
10,000
-31.48%
|
$240,000
$24.45 P/Share
|
|
Mar 19
2021
|
L Patrick Gage Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+23.95%
|
$50,000
$5.88 P/Share
|
|
Mar 12
2021
|
L Patrick Gage Director |
SELL
Open market or private sale
|
Direct |
10,339
-18.82%
|
$217,119
$21.22 P/Share
|
|
Mar 12
2021
|
L Patrick Gage Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,339
+15.65%
|
$72,373
$7.26 P/Share
|
|
Mar 11
2021
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.2%
|
$38,000
$19.9 P/Share
|
|
Mar 08
2021
|
Robert I Blum President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
23,799
-6.25%
|
$452,181
$19.19 P/Share
|
|
Mar 08
2021
|
David Cragg Chief HR & Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,150
-2.52%
|
$78,850
$19.19 P/Share
|
|
Mar 08
2021
|
Ching Jaw SVP Finance & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,150
-4.48%
|
$78,850
$19.19 P/Share
|
|
Mar 08
2021
|
Fady Ibraham Malik EVP Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
7,634
-4.39%
|
$145,046
$19.19 P/Share
|
|
Mar 08
2021
|
Mark A Schlossberg SVP - Legal & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
4,150
-7.55%
|
$78,850
$19.19 P/Share
|
|
Mar 08
2021
|
Robert Wong VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,359
-5.38%
|
$25,821
$19.19 P/Share
|
|
Mar 08
2021
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.3%
|
$95,000
$19.49 P/Share
|
|
Mar 08
2021
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.28%
|
$30,000
$6.0 P/Share
|
|
Mar 02
2021
|
Robert I Blum President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+17.37%
|
-
|
|
Mar 02
2021
|
David Cragg Chief HR & Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+13.17%
|
-
|
|
Mar 02
2021
|
Ching Jaw SVP Finance & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+21.25%
|
-
|
|
Mar 02
2021
|
Fady Ibraham Malik EVP Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+16.75%
|
-
|
|
Mar 02
2021
|
Mark A Schlossberg SVP - Legal & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+31.25%
|
-
|
|
Mar 02
2021
|
Robert Wong VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+28.38%
|
-
|
|
Mar 01
2021
|
Robert I Blum President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,916
-3.19%
|
$188,404
$19.66 P/Share
|
|
Mar 01
2021
|
David Cragg Chief HR & Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,075
-1.46%
|
$39,425
$19.66 P/Share
|
|
Mar 01
2021
|
Ching Jaw SVP Finance & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,384
-2.01%
|
$26,296
$19.66 P/Share
|
|
Mar 01
2021
|
Fady Ibraham Malik EVP Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
2,767
-1.95%
|
$52,573
$19.66 P/Share
|
|
Feb 26
2021
|
Robert I Blum President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
23,799
-7.12%
|
$428,382
$18.73 P/Share
|
|
Feb 26
2021
|
David Cragg Chief HR & Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,379
-2.99%
|
$78,822
$18.73 P/Share
|
|
Feb 26
2021
|
Ching Jaw SVP Finance & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,353
-5.93%
|
$78,354
$18.73 P/Share
|
|
Feb 26
2021
|
Fady Ibraham Malik EVP Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
7,060
-4.74%
|
$127,080
$18.73 P/Share
|
|
Feb 26
2021
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.47%
|
$95,000
$19.33 P/Share
|
|
Feb 26
2021
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.45%
|
$30,000
$6.0 P/Share
|
|
Feb 18
2021
|
Robert I Blum President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
54,548
-7.32%
|
$1,145,508
$21.01 P/Share
|
|
Feb 18
2021
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
83,332
+9.6%
|
$749,988
$9.42 P/Share
|
|
Feb 11
2021
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
1,632
-1.08%
|
$37,536
$23.34 P/Share
|
|
Feb 10
2021
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.61%
|
$115,000
$23.88 P/Share
|
|
Feb 10
2021
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.58%
|
$30,000
$6.0 P/Share
|
|
Jan 29
2021
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.61%
|
$100,000
$20.34 P/Share
|
|
Jan 29
2021
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.58%
|
$30,000
$6.0 P/Share
|
|
Jan 20
2021
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.61%
|
$100,000
$20.41 P/Share
|
|
Jan 20
2021
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.58%
|
$30,000
$6.0 P/Share
|
|
Jan 14
2021
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
12,500
-3.86%
|
$237,500
$19.25 P/Share
|
|
Jan 14
2021
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+3.61%
|
$112,500
$9.42 P/Share
|
|
Jan 04
2021
|
Robert Califf Director |
BUY
Grant, award, or other acquisition
|
Direct |
255
+50.0%
|
$4,845
$19.56 P/Share
|
|
Jan 04
2021
|
L Patrick Gage Director |
BUY
Grant, award, or other acquisition
|
Direct |
958
+4.22%
|
$18,202
$19.56 P/Share
|
|
Jan 04
2021
|
John T Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
511
+26.6%
|
$9,709
$19.56 P/Share
|
|
Jan 04
2021
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
511
+50.0%
|
$9,709
$19.56 P/Share
|
|
Jan 04
2021
|
Sandford D Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
511
+50.0%
|
$9,709
$19.56 P/Share
|
|
Jan 04
2021
|
Wendall Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
511
+50.0%
|
$9,709
$19.56 P/Share
|
|
Jan 04
2021
|
Nancy Wysenski Director |
BUY
Grant, award, or other acquisition
|
Direct |
255
+50.0%
|
$4,845
$19.56 P/Share
|
|
Jan 04
2021
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.61%
|
$100,000
$20.23 P/Share
|